Apremilast

Generic Name
Apremilast
Brand Names
Otezla, Apremilast Accord
Drug Type
Small Molecule
Chemical Formula
C22H24N2O7S
CAS Number
608141-41-9
Unique Ingredient Identifier
UP7QBP99PN
Background

Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the tr...

Indication

Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.

Associated Conditions
Psoriasis Vulgaris (Plaque Psoriasis), Active Psoriatic arthritis, Ulceration of the mouth
Associated Therapies
-
Clinical Trials
Related News

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: Apremilast
Other: Placebo
First Posted Date
2017-04-21
Last Posted Date
2020-05-13
Lead Sponsor
Amgen
Target Recruit Count
303
Registration Number
NCT03123471
Locations
🇺🇸

Dermatologic Surgery Specialists, P.C., Macon, Georgia, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Renstar Medical Research, Ocala, Florida, United States

and more 41 locations

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

Phase 2
Completed
Conditions
Vitiligo
Interventions
Drug: Apremilast
Procedure: NB-UVB phototherapy
First Posted Date
2017-04-21
Last Posted Date
2019-08-28
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
23
Registration Number
NCT03123016
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

Completed
Conditions
Arthritis, Psoriatic
Interventions
Drug: apremilast
First Posted Date
2017-03-31
Last Posted Date
2020-04-29
Lead Sponsor
Amgen
Target Recruit Count
106
Registration Number
NCT03096990
Locations
🇧🇪

CHU St Pierre (César de Paepe), Bruxelles, Belgium

🇧🇪

CHU Brugmann, Bruxelles, Belgium

🇧🇪

Reumaclinic, Genk, Belgium

and more 18 locations

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

Completed
Conditions
Psoriasis
Interventions
Drug: Apremilast
First Posted Date
2017-03-31
Last Posted Date
2020-04-27
Lead Sponsor
Amgen
Target Recruit Count
124
Registration Number
NCT03097003
Locations
🇧🇪

Ste Elisabeth - Namur, Namur, Belgium

🇧🇪

CH Bois Abbaye-Hesbaye, Seraing, Belgium

🇧🇪

Private Practice Lede, Lede, Belgium

and more 19 locations

Vascular Inflammation in Psoriasis - Apremilast

Phase 4
Completed
Conditions
Psoriasis
Cardiovascular Diseases
Interventions
Drug: Apremilast
First Posted Date
2017-03-17
Last Posted Date
2022-11-10
Lead Sponsor
University of Pennsylvania
Target Recruit Count
70
Registration Number
NCT03082729
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

Center for Clinical Studies, Houston, Texas, United States

🇺🇸

Oregon Medical Research Center, Portland, Oregon, United States

and more 4 locations

Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis

First Posted Date
2017-02-10
Last Posted Date
2018-07-24
Lead Sponsor
M.B.A. van Doorn
Target Recruit Count
20
Registration Number
NCT03049267
Locations
🇳🇱

Erasmus University Medical Center, Rotterdam, Netherlands

Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO

Phase 2
Completed
Conditions
Vitiligo
Interventions
Other: Placebo
Drug: Apremilast
First Posted Date
2017-01-31
Last Posted Date
2019-12-04
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Target Recruit Count
80
Registration Number
NCT03036995
Locations
🇫🇷

CHU de Nice - Dermatologie - Hôpital Archet, Nice, Alpes-Maritimes, France

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

Phase 4
Completed
Conditions
Psoriatic Nail
Psoriasis Vulgaris
Psoriasis
Interventions
Drug: Apremilast
First Posted Date
2017-01-16
Last Posted Date
2024-06-06
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
12
Registration Number
NCT03022617
Locations
🇺🇸

The Kirklin Clinic, Birmingham, Alabama, United States

Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

Phase 4
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Apremilast
First Posted Date
2016-12-22
Last Posted Date
2019-03-28
Lead Sponsor
Derm Research, PLLC
Target Recruit Count
20
Registration Number
NCT03000309
Locations
🇺🇸

DermResearch, PLLC, Louisville, Kentucky, United States

A Study of LY2775240 in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: LY2775240
Drug: Placebo
Drug: Apremilast
First Posted Date
2016-11-15
Last Posted Date
2017-11-07
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
35
Registration Number
NCT02963779
Locations
🇸🇬

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy